ABL Bio | Sustainability Performance
Develops bispecific antibodies and antibody-drug conjugates for cancer and neurodegenerative diseases.
2016
South Korea
51 - 200 employees
Biotechnology
$25M - 100M in revenue
N/A in profitability
Sustainability Ranking & Industry Benchmark
#7379
Overall#97
in South Korea#153
in BiotechnologySustainability Maturity
Sustainability Intent
Overview
Governance
TargetsESG scores and exclusionsFinancial Data
Business performanceCapital & innovationAsset manager exclusion
Market cap
Revenue
R&D intensity
Market cap
Revenue
EBITDA
Operating margin
Margin trends
Margin as % of revenue
Gross margin
Operating margin
Net margin
Powered by illuminem
Free cashflow
Capex
R&D intensity
117.2%FY2025
R&D as % of revenue
R&D as % of revenue
Industry benchmark
Powered by illuminem
Return on invested capital
-24.0%FY2026
Return on invested capital (ROIC)
Industry benchmark
Powered by illuminem
Exclusions by region
Reveal data for 2 credits
Institutions excluding by region out of total tracked institutions
Excluding institutions
Reveal data for 2 credits
Institution name, type, screener label
Powered by illuminem andEnvironmental policy coverage
Carbon reduction policy
Not available
Human rights policy
Not available
Recycling policy
Not available
Workplace health & safety policy
Not available
25%
Independent Directors
2 out of 8 incl. management
Overall score
0
Environment
0
Social
0
Governance
0
Exclusion screening
Adult content
Not available
Alcoholic
Not available
Animal testing
Not available
Firearms
Not available
Tobacco
Not available
Gambling
Not available
Nuclear
Not available
Reporting
Not reporting on Sustainability
Not committed to key sustainability initiatives